Wang Jing, Wang Xiaoyu, Zhong Zhenyu, Li Xue, Sun Jiazheng, Li Jie, Huang Jiefeng, Li Yunhai, Ren Guosheng, Li Hongzhong
Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Front Oncol. 2021 Aug 12;11:642571. doi: 10.3389/fonc.2021.642571. eCollection 2021.
Currently, the location of primary tumor was an independent prognostic factor of breast cancer. Tumors in the central and nipple portion (TCNP) had poor prognosis compared to other peripheral quadrants. The breast-conserving therapy (BCT) is becoming increasingly common worldwide in breast cancer operations. However, whether the availability of BCT was performed for TCNP remained a matter of debate. We sought to investigate whether BCT was suitable for TCNP with respect to survival outcomes, compared with mastectomy therapy.
Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, we obtained TCNP breast cancer patients diagnosed during the period of 2010-2015. One-to-one (1:1) propensity score matching (PSM) was applied to construct a matched sample consisting of pairs of BCT and mastectomy groups. Univariate and multivariate Cox proportional hazard models were applied to estimate the factors associated with breast cancer-specific survival (BCSS) and overall survival (OS). Survival analysis was performed with the Kaplan-Meier method.
In the overall cohort, a total of 9,900 patients were enrolled. We found that patients with BCT showed significantly better BCSS (log-rank, < 0.001) and OS (log-rank, < 0.001) than the mastectomy group before PSM. The same finding was also shown in 5,820 patients after PSM. Additionally, none of the subgroups, including age, sex, race, histological grade, AJCC stage, and molecular subtype undergoing mastectomy therapy, had better BCSS than BCT.
Our study was the first research to show that BCT exhibited superior prognosis in the cohort of TCNP from SEER databases than mastectomy therapy. This finding could provide a cue for treatment strategies for suitable TCNP patients, especially those with a strong willingness to conserve their breasts.
目前,原发肿瘤位置是乳腺癌的一个独立预后因素。与其他外周象限的肿瘤相比,位于乳腺中央和乳头部位(TCNP)的肿瘤预后较差。保乳治疗(BCT)在全球乳腺癌手术中越来越普遍。然而,对于TCNP是否可行BCT仍存在争议。我们试图研究与乳房切除术相比,就生存结果而言BCT是否适用于TCNP。
利用监测、流行病学和最终结果(SEER)数据库,我们获取了2010年至2015年期间诊断的TCNP乳腺癌患者。采用一对一(1:1)倾向评分匹配(PSM)构建由BCT组和乳房切除术组配对组成的匹配样本。应用单变量和多变量Cox比例风险模型来估计与乳腺癌特异性生存(BCSS)和总生存(OS)相关的因素。采用Kaplan-Meier方法进行生存分析。
在整个队列中,共纳入9900例患者。我们发现,在PSM之前,BCT组患者的BCSS(对数秩检验,<0.001)和OS(对数秩检验,<0.001)显著优于乳房切除术组。在PSM后的5820例患者中也显示出相同的结果。此外,接受乳房切除术治疗的亚组,包括年龄、性别、种族、组织学分级、美国癌症联合委员会(AJCC)分期和分子亚型,均没有比BCT更好的BCSS。
我们的研究是首次表明BCT在SEER数据库的TCNP队列中比乳房切除术具有更好预后的研究。这一发现可为合适的TCNP患者,尤其是那些有强烈保乳意愿的患者的治疗策略提供线索。